Dovonex (Calcipotriene)
calcipotriene · also known as calcipotriol
Calcipotriene Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Plaque psoriasis (body) | Adults (cream, ointment); adults and children ≥4 years (foam) | Monotherapy or adjunctive with topical corticosteroids / phototherapy | FDA Approved |
| Plaque psoriasis (scalp) | Adults (scalp solution); adults and children ≥4 years (foam) | Monotherapy or adjunctive | FDA Approved |
Calcipotriene was the first topical vitamin D analogue approved for psoriasis (1993 in the US) and remains a cornerstone of topical psoriasis management. It is positioned as first-line topical therapy either alone or in combination with topical corticosteroids for mild-to-moderate plaque psoriasis. The combination product calcipotriene/betamethasone dipropionate (Taclonex, Enstilar) is frequently prescribed for enhanced efficacy. Clinical improvement is typically detectable within 2 weeks, with efficacy demonstrated at 8 weeks in pivotal trials. Guidelines support long-term use of topical vitamin D analogues for up to 52 weeks.
Vitiligo: Used in combination with phototherapy to promote repigmentation. Evidence quality: moderate (small controlled trials).
Morphoea (localised scleroderma): Some case series report benefit. Evidence quality: low.
Ichthyosis and other keratinisation disorders: Limited evidence from case reports. Evidence quality: very low.
Calcipotriene Dosing
Dosing by Formulation
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Plaque psoriasis (body) — cream | Thin layer BID | Thin layer BID | 100 g/week | Rub in gently and completely; safety demonstrated for 8 weeks Avoid application to face (FDA PI) |
| Plaque psoriasis (body) — ointment | Thin layer QD–BID | Thin layer QD–BID | 100 g/week | Once-daily dosing may have similar efficacy to twice daily (FDA PI); ointment may be slightly more effective than cream Avoid face; improvement in ~2 weeks |
| Scalp psoriasis — solution | Apply to lesions BID | Apply to lesions BID | 100 g/week | Comb hair to remove scaly debris first; part hair and apply directly to lesions Avoid spreading to forehead; safety demonstrated for 8 weeks |
| Plaque psoriasis (body and scalp) — foam (Sorilux) | Thin layer BID | Thin layer BID | 100 g/week | Shake well; dispense into palm; rub until foam disappears Approved for ≥4 years; flammable propellant — avoid fire/flame |
| Combination with topical corticosteroid (sequential or alternating) | Varies by regimen | Calcipotriene BID weekdays; corticosteroid BID weekends (one approach) | 100 g/week calcipotriene | Multiple regimens used: sequential, weekend/weekday, or AM/PM split Reduces corticosteroid exposure while maintaining efficacy; up to 52 weeks per guidelines |
| Paediatric use (≥4 years) — foam only | Thin layer BID | Thin layer BID | 100 g/week/m² BSA | Higher ratio of skin surface area to body mass increases systemic absorption risk Cream and ointment: paediatric safety not established per Dovonex PI |
To minimise the risk of hypercalcaemia, total weekly application should not exceed 100 g (some sources recommend a daily maximum of 15 g). The 100 g/week limit applies across all formulations. When calcipotriene is used in combination with the fixed-dose calcipotriene/betamethasone dipropionate product, the total calcipotriene exposure from both products must be considered. Patients should not apply calcipotriene to more than approximately 30–40% of body surface area.
Pharmacology
Mechanism of Action
Calcipotriene is a synthetic analogue of calcitriol (1,25-dihydroxyvitamin D3) that binds with comparable affinity to the intracellular vitamin D receptor (VDR) in keratinocytes. Upon binding, the VDR forms a heterodimer with the retinoid X receptor (RXR), and this complex translocates to the nucleus where it binds to vitamin D response elements (VDREs) in target gene promoters. This transcriptional regulation produces two key therapeutic effects: inhibition of keratinocyte proliferation and promotion of keratinocyte differentiation, thereby normalising the accelerated epidermal turnover characteristic of psoriasis and restoring the granular layer. Calcipotriene also modulates immune function by reducing CD8+ and IL-17+ T cell activity and dampening inflammatory cytokine signalling. Critically, calcipotriene retains the antiproliferative and pro-differentiating effects of calcitriol while being approximately 200 times less potent in regulating calcium metabolism, making it suitable for topical use with a substantially lower risk of hypercalcaemia.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | ~6% (±3% SD) absorbed systemically from psoriatic skin; ~5% (±2.6% SD) from normal skin (radiolabelled ointment studies) | Low systemic absorption limits risk of hypercalcaemia at recommended doses; plasma levels typically below limit of quantification (10 pg/mL) |
| Distribution | Bound to specific vitamin D plasma transport proteins; disposition similar to endogenous vitamin D | Follows natural vitamin D handling pathways; minimal systemic accumulation expected |
| Metabolism | Rapidly converted to inactive metabolites within 24 h of application; metabolic pathway parallels natural calcitriol; recycled via liver | Primary metabolites are much less potent than parent compound; rapid inactivation provides safety margin |
| Elimination | Excreted in bile (similar to calcitriol); exact renal/faecal proportions not characterised for topical use | Follows endogenous vitamin D3 elimination; short effective half-life limits systemic exposure |
Side Effects
Side effect data are derived from controlled clinical trials reported in the FDA prescribing information for Dovonex (cream, ointment, scalp solution) and Sorilux (foam). Adverse effects are predominantly local skin reactions at the application site. Calcipotriene has no boxed warning and carries a favourable systemic safety profile owing to its low percutaneous absorption.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Burning, stinging, tingling (scalp solution) | ~23% | Transient; most common with scalp solution; usually resolves within minutes of application |
| Burning, itching, skin irritation (cream/ointment) | 10–15% | Lesional and perilesional; dose-dependent; may improve with continued use or formulation switch |
| Rash (scalp solution) | ~11% | Localised to application area; assess for allergic contact dermatitis if persistent |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Erythema | 1–10% | Localised redness at application site; usually mild |
| Dry skin / peeling | 1–10% | Perilesional dryness; manage with concurrent emollients |
| Dermatitis / worsening of psoriasis | 1–10% | Includes worsening of existing plaques and development of facial/scalp psoriasis; discontinue if significant worsening |
| Pruritus | 1–10% | Localised to treated areas; differentiate from underlying psoriasis itch |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Hypercalcaemia | <1% (with excessive use) | Days to weeks with overuse | Discontinue until serum calcium normalises; reversible on cessation; associated with use exceeding 100 g/week |
| Allergic contact dermatitis | Rare | Days to weeks after initiation | Discontinue; confirm with diagnostic patch testing (FDA PI); reported specifically with cream formulation |
Perilesional irritation is the most common reason patients discontinue calcipotriene. Strategies to improve tolerability include switching formulations (the cream is generally better tolerated than the ointment for some patients), reducing application frequency to once daily, applying an emollient barrier to perilesional skin before calcipotriene, and ensuring the product is not applied to the face or intertriginous areas (though some studies suggest cautious off-label facial use). Patients experiencing persistent irritation may benefit from transitioning to a fixed-dose combination with betamethasone dipropionate, which provides anti-inflammatory protection and reduces irritation.
Drug Interactions
Calcipotriene has minimal systemic absorption and no known clinically significant drug-drug interactions based on formal pharmacokinetic studies. The primary interaction concern is additive effects on calcium metabolism when combined with other vitamin D-related products. The FDA PI does not list any specific drug interaction contraindications.
Monitoring
-
Serum Calcium
If using extensively or on large BSA
Trigger-based Not routinely required for standard use. Check if applying to >30% BSA, using >100 g/week, or if symptoms of hypercalcaemia develop (nausea, increased thirst, confusion, fatigue). Discontinue until calcium normalises if elevated. Elevations are transient and reversible. -
Local Skin Reactions
Each follow-up visit
Routine Assess for burning, irritation, erythema, and perilesional dermatitis. Worsening of psoriasis (including new facial or scalp involvement) occurred in 1–10% of patients. Consider allergic contact dermatitis if irritation is disproportionate; patch testing may be warranted (cream formulation). -
Treatment Response
2 weeks; then 8 weeks
Routine Initial improvement expected within 2 weeks. Formal efficacy assessment at 8 weeks (controlled trial endpoint). If no improvement at 8 weeks, reconsider treatment plan. In open-label studies, ~50% of patients achieved satisfactory response by 16 weeks and no longer required treatment. -
Paediatric Growth
Periodically for long-term paediatric use
Trigger-based Children have a higher skin surface area to body mass ratio, increasing risk of systemic absorption. Monitor calcium and growth parameters in children receiving prolonged treatment.
Contraindications & Cautions
Absolute Contraindications
- Hypercalcaemia—calcipotriene may further elevate serum calcium
- Evidence of vitamin D toxicity
- Hypersensitivity to calcipotriene or any component of the formulation
Relative Contraindications (Specialist Input Recommended)
- Application to the face—not recommended per FDA PI due to increased irritation risk; some studies support cautious off-label facial use in selected patients
- Extensive body surface area involvement (>30–40% BSA)—increased risk of systemic absorption and hypercalcaemia
Use with Caution
- Paediatric patients—higher skin-surface-area-to-mass ratio increases systemic absorption risk; foam approved ≥4 years, cream/ointment safety not established in children per Dovonex PI
- Elderly patients (≥65 years)—statistically more severe skin-related adverse events observed with ointment in patients over 65 compared to younger adults (FDA PI)
- Concurrent UV exposure—animal data suggest calcipotriene may enhance UVR-induced skin tumour formation; counsel patients to limit sun exposure and avoid tanning beds
- Concurrent high-dose vitamin D or calcium supplementation—monitor serum calcium
- Foam formulation (Sorilux)—contains flammable propellant; avoid fire, flame, and smoking during and immediately after application
Patient Counselling
Purpose of Therapy
Calcipotriene is a topical form of vitamin D that is applied directly to psoriasis plaques. It works by slowing the rapid growth of skin cells and encouraging them to mature normally, which reduces the thickness, scaling, and redness of psoriasis patches. It is not a steroid and can be used long-term as part of your psoriasis management plan.
How to Use
Apply a thin layer to the affected areas only and rub in gently and completely. Wash your hands thoroughly after application unless your hands are the treated area. Avoid getting the medication on your face, in your eyes, or on areas of skin without psoriasis. For scalp treatment, comb hair first to remove loose scales, then part hair and apply directly to the affected area. Improvement usually begins within 2 weeks, but it may take up to 8 weeks to see full benefit.
Sources
- LEO Pharma / Glenmark Pharmaceuticals. Dovonex (calcipotriene) ointment and cream 0.005%. Full prescribing information. Revised 2025. accessdata.fda.govPrimary source for dosing, adverse reaction rates (10–15% irritation for cream/ointment), absorption data (6%), and contraindications.
- Dovonex (calcipotriene) scalp solution 0.005%. Prescribing information. accessdata.fda.govSource for scalp solution adverse reaction rates (23% burning/stinging, 11% rash) and geriatric data.
- Mayne Pharma. Sorilux (calcipotriene) foam 0.005%. Full prescribing information. rxlist.comSource for foam-specific data including paediatric approval (≥4 years), pharmacokinetics (plasma levels below LOQ), and flammability warnings.
- Kragballe K. Treatment of psoriasis with calcipotriol and other vitamin D analogues. J Am Acad Dermatol. 1992;27(6 Pt 1):1001–1008. doi:10.1016/0190-9622(92)70302-vLandmark early trial establishing calcipotriol efficacy and the ~200-fold reduced calcaemic potency relative to calcitriol.
- Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol propionate ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol. 1996;35(2 Pt 1):268–269. doi:10.1016/S0190-9622(96)90344-4Demonstrated superiority of calcipotriene-corticosteroid combination over either agent alone, establishing the rationale for combination therapy.
- Sorilux foam phase III trials. Two identical randomised double-blind vehicle-controlled 8-week studies (n = 659). Data summarised in Sorilux PI. Established efficacy of calcipotriene foam in plaque psoriasis (ISGA 0/1 response) and confirmed safety in adolescents and adults.
- Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–659. doi:10.1016/j.jaad.2008.12.032AAD guideline positioning calcipotriene as first-line topical therapy for mild-to-moderate psoriasis, with long-term use recommendations up to 52 weeks.
- Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and the use of retinoids and phototherapy. J Am Acad Dermatol. 2021;84(6):1551–1569. doi:10.1016/j.jaad.2021.02.071Updated AAD-NPF guideline addressing combination vitamin D analogue and corticosteroid regimens for long-term management.
- Bikle DD. Vitamin D regulated keratinocyte differentiation. J Cell Biochem. 2004;92(3):436–444. doi:10.1002/jcb.20095Detailed review of VDR-mediated keratinocyte differentiation pathways explaining the antiproliferative mechanism relevant to calcipotriene.
- Calcipotriene therapeutic cheat sheet. Next Steps in Dermatology. 2024. nextstepsinderm.comClinical summary confirming 100 g/week and 15 g/day maximum dosing limits and formulation-specific considerations.
- DailyMed. Calcipotriene ointment USP 0.005%. National Library of Medicine. dailymed.nlm.nih.govStructured FDA label for generic calcipotriene ointment providing absorption data, open-label extension safety findings, and formulation details.